Findings

What do systematic reviews say?

7 questions · 8 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 87.5%High 1 · 12.5%

Altered WBRT fractionation schedules vs WBRT control

Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases

Altered WBRT fractionation schedules probably leads to higher overall survival: lower‐dose WBRT vs control WBRT (3000 cGy/10 daily… compared with WBRT control (moderate certainty).

2 findings from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
HR 1.21 [1.04, 1.4]
Studies not reported
Moderate
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate

Altered WBRT fractionation schedules vs WBRT control

Overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT (2000 cGy/4‐5 daily fractions)No. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases

Altered WBRT fractionation schedules showed no clear difference in overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT… compared with WBRT control (moderate certainty).

1 finding from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
HR 1.18 [0.89, 1.56]
Studies not reported
Moderate

Altered WBRT fractionation schedules vs WBRT control

Adverse effectsNo. of participants: 1754(9 RCTs) · patients with newly diagnosed multiple brain metastases

1 finding from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Altered WBRT fractionation schedules vs WBRT control

Symptom controlNo. of participants: 1814(3 RCTs) · patients with newly diagnosed multiple brain metastases

1 finding from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Altered WBRT fractionation schedules vs WBRT control

Overall brain controlNo. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases

1 finding from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Altered WBRT fractionation schedules vs WBRT control: neurological function improvement

Neurological function improvement: lower‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1612(5 RCTs) · patients with newly diagnosed multiple brain metastases

Altered WBRT fractionation schedules probably leads to higher neurological function improvement: lower‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).

1 finding from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
OR 1.74 [1.06, 2.84]
Studies not reported
Moderate

Altered WBRT fractionation schedules vs WBRT control: neurological function improvement

Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases

Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).

1 finding from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate